The role of immunomodulatory therapy in the treatment of acute respiratory viral infections in patients with year-round allergic rhinitis
- 作者: Trukhan D.I.1, Bagisheva N.V.1, Nesterova K.I.1, Mordyk A.V.1, Alekseenko V.A.2, Moiseeva M.V.2, Kalashnikova N.M.2, Neshcheretneva V.N.2
-
隶属关系:
- Omsk State Medical University
- Omsk City Polyclinic No. 12
- 期: 卷 34, 编号 8 (2023)
- 页面: 39-43
- 栏目: Pharmacology
- URL: https://journals.eco-vector.com/0236-3054/article/view/569055
- DOI: https://doi.org/10.29296/25877305-2023-08-07
- ID: 569055
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Objective. To assess the effectiveness and safety of the combined medicine interferon alpha-2b + loratadine (Grippferon® with loratadine, nasal ointment) for the prevention and treatment of acute respiratory viral infections (ARVI) in patients with year-round allergic rhinitis.
Materials and Methods. A total of 154 patients were included in the study and divided into four groups: group 1A patients (n=37) received the combined medicine interferon alpha-2b + loratadine (Grippferon® with loratadine) 5 times a day for 7 days for the ARVI treatment; in group 2A (n=41) standard therapy was carried out in accordance with the clinical guidelines for the ARVI treatment in adult patients (2021). Group 1B (n=38) patients used the combined medicine interferon alpha-2b + loratadine once a day for 7 days for the ARVI prevention; in group 2B patients (n=38) ARVI prevention was not conducted. There were 75 (48.7%) men and 79 (51.3%) women, aged 22-45 years.
Results. During treatment with the combined medicine interferon alpha-2b + loratadine in group 1A patients there was a significant decrease in respiratory manifestations (such as nasal congestion, rhinorrhoea, sneezing) by comparing with group 2A patients. Rhinocytogram analysis results showed that the use of the combined medicine interferon alpha-2b + loratadine contributed to the reduction in the intensity and severity of inflammatory (leukocyte count) and allergic (eosinophils) responses. In group 1B patients, who received the medicine interferon alpha-2b + loratadine for the ARVI prevention, we noted that during three observation months 3 times less patients got acute respiratory infections by comparing with group 2B patients.
Conclusion. The received study results demonstrate that the use of topical medicine interferon alpha-2b + loratadine in patients with concomitant acute respiratory viral infections and year-round allergic rhinitis shortens the ARVI treatment period. The preventive use of the given medicine allows us to reduce the number of ARVI in patients with year-round allergic rhinitis.
全文:
作者简介
D. Trukhan
Omsk State Medical University
编辑信件的主要联系方式.
Email: ppi100@mail.ru
ORCID iD: 0000-0002-1597-1876
Dr Med. Sci
俄罗斯联邦, OmskN. Bagisheva
Omsk State Medical University
Email: ppi100@mail.ru
ORCID iD: 0000-0003-3668-1023
Cand. of Med. Sci.
俄罗斯联邦, OmskK. Nesterova
Omsk State Medical University
Email: ppi100@mail.ru
ORCID iD: 0000-0002-9793-7179
Dr Med. Sci
俄罗斯联邦, OmskA. Mordyk
Omsk State Medical University
Email: ppi100@mail.ru
ORCID iD: 0000-0001-6196-7256
Dr Med. Sci., Professor
俄罗斯联邦, OmskV. Alekseenko
Omsk City Polyclinic No. 12
Email: ppi100@mail.ru
俄罗斯联邦, Omsk
M. Moiseeva
Omsk City Polyclinic No. 12
Email: ppi100@mail.ru
ORCID iD: 0000-0003-3458-9346
Cand. of Med. Sci
俄罗斯联邦, OmskN. Kalashnikova
Omsk City Polyclinic No. 12
Email: ppi100@mail.ru
俄罗斯联邦, Omsk
V. Neshcheretneva
Omsk City Polyclinic No. 12
Email: ppi100@mail.ru
俄罗斯联邦, Omsk
参考
- Федоскова Т.Г. Особенности ведения больных круглогодичным аллергическим ринитом при острых респираторных вирусных инфекциях. РМЖ. 2011; 19 (8): 518–21 [Fedoskova T.G. Osobennosti vedeniya bol'nykh kruglogodichnym allergicheskim rinitom pri ostrykh respiratornykh virusnykh infektsiyakh. RMJ. 2011; 19 (8): 518–21 (in Russ.)].
- Ненашева Н.М., Шиленкова В.В. Контроль симптомов аллергического ринита у взрослых лиц в Российской Федерации: результаты онлайн-опроса. РМЖ. Медицинское обозрение. 2021; 5 (1): 25–31 [Nenasheva N.M., Shilenkova V.V. Control of allergic rhinitis symptoms in adults in the Russian Federation: online survey results. Russian Medical Inquiry. 2021; 5 (1): 25–31 (in Russ.)]. doi: 10.32364/2587-6821-2021-5-1-25-31
- Gani F., Lombardi C., Barrocu L. et al. The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. Clin Mol Allergy. 2018; 16: 4. doi: 10.1186/s12948-018-0082-y
- Аллергический ринит. Клинические рекомендации. 2020; 70 с. [Allergicheskii rinit. Klinicheskie rekomendatsii. 2020; 70 р. (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/265_2
- Острые респираторные вирусные инфекции (ОРВИ) у взрослых. Клинические рекомендации. 2021; 64 с. [Ostrye respiratornye virusnye infektsii (ORVI) u vzroslykh. Klinicheskie rekomendatsii. 2021; 64 р. (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/724_1
- Трухан Д.И., Алексеенко В.А., Калашникова Н.М. и др. Сравнительный опыт применения комбинированного лекарственного препарата интерферона альфа-2b с бетаметазоном и азеластина в терапии поллиноза. Врач. 2022; 33 (5): 68–77 [Trukhan D., Alekseenko V., Kalashnikova N. et al. Comparative experience of combined medicine interferon alpha-2b + betamethasone and azelastine in the treatment of pollinosis. Vrach. 2022; 33 (5): 68–77 (in Russ.)]. doi: 10.29296/25877305-2022-05-15
- Трухан Д.И., Алексеенко В.А., Калашникова Н.М. и др. Сравнительный опыт применения комбинированного препарата интерферона альфа-2b с бетаметазоном и олапатадина с мометазоном для местной терапии обострений поллиноза. Врач. 2022; 33 (9): 22–31 [Trukhan D., Alekseenko V., Kalashnikova N. et al. Comparative experience of combined medicine interferon alpha-2b + betamethasone and olopatadine with momethasone in the topical treatment of pollinosis exacerbations. Vrach. 2022; 33 (9): 22–31 (in Russ.)]. doi: 10.29296/25877305-2022-09-04
- Трухан Д.И., Алексеенко В.А., Калашникова Н.М. и др. Опыт применения комбинированного препарата рекомбинантного интерферона альфа-2b в лечении аллергических ринитов. Врач. 2021; 32 (3): 73–81 [Trukhan D., Alekseenko V., Kalashnikova N. et al. The use of combined recombinant interferon alpha-2b medications in the treatment of allergic rhinitis. Vrach. 2021; 32 (3): 73–81 (in Russ.)]. doi: 10.29296/25877305-2021-03-13
- Гапонюк П.Я. Новый подход к лечению больных с аллергическим ринитом. Аллергология и иммунология. 2008; 9: 277 [Gaponyuk P.Ya. New approach to the treatment of patients with allergic rhinitis. Allergology and Immunology. 2008; 9: 277 (in Russ.)].
- Caimmi D., Baiz N., Sanyal S. et al. Discriminating severe seasonal allergic rhinitis. Results from a large nation-wide database. PLoS One. 2018; 13 (11): e0207290. doi: 10.1371/journal.pone.0207290
- Léger D., Bonnefoy B., Pigearias B. et al. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. Allergy Asthma Clin Immunol. 2017; 16: 13–36. doi: 10.1186/s13223-017-0208-7
- Roxbury C., Qiu M., Shargorodsky J. et al. Association Between Rhinitis and Depression in United States Adults. J Allergy Clin Immunol Pract. 2019; 7 (6): 2013–20. doi: 10.1016/j.jaip.2019.02.034
补充文件
